OncoSec Medical

OncoSec Medical EBIT per Share

Delisted

The EBIT per Share of OncoSec Medical (ONCS) as of Oct 20, 2026 is -20.72 USD. In the previous year, EBIT per Share was -32.35 USD — a change of -35.96% (higher).

EBIT per Share

-20.72USD

YoY

-35.96%

Last updated:

EBIT per Share of OncoSec Medical is 2022 -20.72 USD. EBIT per Share of OncoSec Medical was 2021 -32.35 USD. It decreases by -35.96% higher compared to the previous year.

The OncoSec Medical EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
-94.87 USD
Jan 1, 2020
-57.76 USD
Jan 1, 2021
-32.35 USD
Jan 1, 2022
-20.72 USD
Jan 1, 2023 (e)
0.00 USD
Jan 1, 2024 (e)
0.00 USD
Jan 1, 2025 (e)
-19.38 USD
Jan 1, 2026 (e)
-19.41 USD
The OncoSec Medical EBIT per Share history
YEAREBIT per ShareYoY
est-19.41USD+0.16%
est-19.38USD—
est0.00USD—
est0.00USD-100.00%
-20.72USD-35.96%
-32.35USD-43.99%
-57.76USD-39.12%
-94.87USD-52.08%
-197.97USD-15.29%
-233.72USD-34.75%
-358.17USD-2.59%
-367.70USD+33.25%
-275.94USD-5.41%
-291.74USD-19.10%
-360.59USD+205.96%
-117.86USD+6,653.78%
-1.75USD-19.45%
-2.17USD+369.10%
-0.46USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OncoSec Medical Stock analysis

What does OncoSec Medical do? OncoSec Medical Inc is a US-based company specializing in the development of cancer treatment methods through immunotherapy. The company was founded in 2011 and is headquartered in San Diego, California. The history of OncoSec Medical Inc began with the idea of improving tumor treatments through electroporation. Electroporation is a process that uses electric pulses to increase the permeability of cell membranes. This facilitates the exchange of molecules and the uptake of drugs, which is used in the treatment of cancer cells. The business model of OncoSec Medical Inc is based on the development and commercialization of immunotherapies to combat cancer. Electroporation is used to locally infect tumor lesions with reactivated T-cells and other immune cells to generate an immune response. OncoSec Medical Inc has developed a proprietary platform called ImmunoPulse, which combines electroporation and immunotherapy. The company is divided into various divisions, including research and development, clinical trials, manufacturing, and distribution. Research and development focus on identifying potential immunotherapies and testing drug candidates. Clinical trials are designed to confirm the effectiveness and safety of therapies through clinical testing. Manufacturing involves the production of drug candidates and clinical preparations in accordance with Good Manufacturing Practices (GMPs). Distribution includes the sale and marketing of approved therapies to patients and healthcare providers. OncoSec Medical Inc offers a variety of immunotherapies for the treatment of various types of cancer. This includes ImmunoPulse IL-12 therapy, which is used to treat metastatic melanoma. The company is also working on several other therapies, including the Verapamil-Plus-IL-2 protocol for the treatment of breast and prostate cancer. In summary, OncoSec Medical Inc is an emerging biotechnology company specializing in the development and commercialization of immunotherapies to combat cancer. Through its proprietary ImmunoPulse platform and extensive research and development, the company strives to provide effective and safe treatment options for cancer patients, fully harnessing the potential of immunotherapy. OncoSec Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OncoSec Medical stock

EBIT per Share of OncoSec Medical is -20.72 USD in 2022.

EBIT per Share of OncoSec Medical changed from -32.35 USD to -20.72 USD, representing a -35.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share OncoSec Medical since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — OncoSec Medical

All Key Metrics — OncoSec Medical